Tempus AI Soars on Cancer Vaccine Breakthrough and Pending Acquisition

Tempus AI's stock price surged this week after Merck and Moderna published encouraging trial results for their cancer treatment. The company is set to acquire Personalis, which provided technologies that aided in the development of Merck and Moderna's cancer vaccine.

The Phase 3 trial data showed that patients who received the combined treatment of Merck's Keytruda immunotherapy and Moderna's mRNA vaccine had significant benefits compared to those who only took Keytruda. This bodes well for Tempus, as its deal with Personalis is expected to close late this year or early in 2027.

The acquisition could be a smart move for Tempus, given the apparent success of personalized vaccines developed with Personalis's technology. The company may see strong tailwinds from the precision medicine and genomic diagnostics technologies that are a big part of its long-term growth story.